Abstract
SERUM ZINE AND COPPER LEVELS OF EPILEPTIC PATIENTS BEFORE AND AFTER DRUG
THERAPY
✓ In 42 epileptic patients the serum levels of copper (Cu) and zinc (zn) were determined before drug therapy had begun by atomic absorption spectrophotometry. In 16 of these patients the serum levels of Zn and Cu were also determined at least 3 months after therapy. The results were compared with each other and a control comprising 20 healthy individuals. The mean serum Zn levels of the patients prior to drug therapy, undergoing therapy and the control group were 79.42+17.7 , 83.6+18.3 and 86.95+ 18.61 Hg/100 ml respectively. The mean serum copper levels of the patients prior to therapy, undergoing therapy and the control group were 117+ 21.9, 123.1+18.4 and 119.4, respectively. There were no statistically significant differences bet¬ween the groups (p> 0.05). Serum Zn levels decreased in patients using diphenylhydantoin (DDH) and increased in patients using carbamazepin (CBZ). But, neither of these results were statistically significant. However, serum Cu levels increased significantly in patients using CBZ (p<0.05) while there were no increase in patients using DPH. We conclude that there were no significant changes in the serum Cu and Zn levels of epileptic patients before drug therapy as compared to controls. The significant increase in serum Cu levels of epileptic patients after CBZ therapy as compared to the levels before therapy could be due to the central or peripheral acti¬ons of CBZ and needs further investigation
42 epilepsili hastada tedavi öncesi serum çinko (Zn) ve bakır (Cu)' değerleri ile aynı gruptan 16 hastada tedavi sonrası serum Cu ve Zn değerleri atomik absorbsiyon spektrofotometresi ile tayin edildi. Sonuçlar birbirleriyle ve 20 sağlıklı kişiden oluşan kontrol grubu sonuçlarıyla karşılaştırıldı. Serum Zn düzeyi ortalaması hasta grubunda tedavi öncesi 79,42±17,7 |igr/100 ml tedavi sonrası 83,6+18,3ng/100 ml, kontrol grubunda 86,95±18,6 |igr/100 bulundu. Serum Cu düzeyi ortalaması hasta grubunda tedavi öncesi 117±21,9 p.gr/100ml, tedavi sonrası 123,1±18,4 Hgr/100 ml, kontrol grubunda 119,4+ 19.4 |igr/100 ml bulundu. Gruplar arasında önemli fark yoktu(p>0,05). Difenilhidantoin (DPH) kullanan hastalarda serum Zn düzeyinde azalma, Cu düzeyinde ise artış saptandı. Fakat sonuçlar istatistiksel olarak anlamsızdı. Yalnız karbamazepin (CBZ) kullanan hastalarda serum Cu düzeyinde anlamlı artış görüldü (p<0.05).
Sonuç olarak epileptik hastaların serum Cu ve Zn düzeylerinde ilaç tedavisi öncesi kontrol gru¬buna göre önemli fark olmadığı, CBZ tedavisinden sonra hastaların serum Cu düzeylerinde görülen artışın karbamazepinin santral veya periferik etkilerine bağlı olabileceği düşünüldü.
Keywords
Details
| Primary Language | English |
|---|---|
| Journal Section | Basic Medical Sciences |
| Authors | |
| Publication Date | December 22, 2009 |
| Submission Date | November 23, 2009 |
| Published in Issue | Year 1992 Volume: 9 Issue: 2 |
Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.